Ty Sperl became the first patient in the world to receive prime editing as a treatment for granulomatous disease, Global News reports. He was diagnosed at age five and has been taking antibiotics and antifungals for 14 years to control the condition. A bone marrow transplant could have been a solution, but a suitable donor has not been found for Ty.
Tai was enrolled in a pilot clinical trial examining the efficacy and safety of prime editing for the treatment of rare genetic diseases. As part of the therapy, his blood stem cells were extracted, edited without double-strand breaks, and then reintroduced into his body.
The treatment resulted in rapid restoration of immune function and was safe. In addition to Tai, a similar procedure was performed on another patient, who also showed a complete recovery.
"I've been taking a lot of pills my whole life, and now it's all in the past; I don't need to take medication anymore. It's just amazing," Tai said.
Scientists call the results a milestone for the healthcare system, offering hope to families with rare genetic diseases.
Meanwhile, CRISPR technology has previously demonstrated excellent results in patients with high cholesterol. Even in resistant cases, levels were reduced by up to 80%.
